JonesTrading analyst Sean Kim PhD reiterated a Buy rating on Opthea Limited Sponsored ADR (OPT – Research Report) today and set a price target of $15.00. The company’s shares closed today at $2.19.
Kim PhD covers the Healthcare sector, focusing on stocks such as Arcutis Biotherapeutics, EyePoint Pharmaceuticals, and CymaBay Therapeutics. According to TipRanks, Kim PhD has an average return of 8.2% and a 37.88% success rate on recommended stocks.
Opthea Limited Sponsored ADR has an analyst consensus of Strong Buy, with a price target consensus of $15.00, a 584.93% upside from current levels. In a report released yesterday, Oppenheimer also maintained a Buy rating on the stock with a $16.00 price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $6.25 and a one-year low of $2.18. Currently, Opthea Limited Sponsored ADR has an average volume of 13.75K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused primarily on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea’s development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.
Read More on OPT:
- Opthea price target lowered to $16 from $31 at Oppenheimer
- Opthea to Present at the H.C. Wainwright 25th Annual Global Investment Conference
- Opthea Successfully Completes Institutional Offer and Increases Capital Raising to A$90.0m (US$57.6 million¹)
- Opthea Ltd (ADR) trading halted, news pending
- Oppenheimer biotechnology analysts to hold an analyst/industry conference call
